Study Title

novartis

A Phase Ib Dose Finding Study Assessing Safety and Activity of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC) in Combination With Carboplatin, Etoposide and Tislelizumab in Induction and With Tislelizumab in Maintenance Treatment Phase

Study Details

Description:

This study aims to establish a safe and well tolerated dose of [177Lu]Lu-DOTA-TATE in combination with carboplatin, etoposide, and tislelizumab in induction treatment and with tislelizumab in maintenance treatment in newly diagnosed patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC).

Sponsor:

Novartis

Contacts:

Novartis Pharmaceuticals

novartis.email@novartis.com

1-888-669-6682 or +41613241111

Government Study Link:

NCT05142696 - Click here to see study on

ClinicalTrials.gov

Patient Education

Patient Education Not Yet Provided

Publications

Publications Not Yet Provided

Locations

Not yet provided. Contact Novartis Pharmaceuticals for more information.

1-888-669-6682 or +41613241111

novartis.email@novartis.com

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468